Cubist Systematic Strategies, LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $1.81 Million - $1.99 Million	46,473 Added 178.24%	72,546 $2.97 Million
Q1 2024 May 15, 2024	SELL	$40.88 - $43.27 $1.18 Million - $1.25 Million	-28,902 Reduced 52.57%	26,073 $1.1 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $1.11 Million - $2.33 Million	54,975 New	54,975 $2.33 Million
Q4 2022 Feb 14, 2023	SELL	$25.35 - $31.96 $687,542 - $866,819	-27,122 Reduced 81.68%	6,085 $191,000
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $846,778 - $1.38 Million	33,207 New	33,207 $938,000
Q1 2022 May 16, 2022	SELL	$23.5 - $35.38 $199,421 - $300,234	-8,486 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$29.21 - $44.64 $272,324 - $416,178	-9,323 Reduced 52.35%	8,486 $275,000
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $376,493 - $687,994	17,709 Added 17709.0%	17,809 $525,000
Q2 2021 Aug 16, 2021	SELL	$12.56 - $29.69 $3,768 - $8,907	-300 Reduced 75.0%	100 $3,000
Q1 2021 May 17, 2021	SELL	$12.37 - $17.74 $145,038 - $208,001	-11,725 Reduced 96.7%	400 $5,000
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $119,067 - $221,523	12,125 New	12,125 $201,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.